DENISE BLACKBOURNE: Open Payments
NPI 1356623961 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$315 in 13 payments from 11 companies in 2025. Trend: 2023 $158 · 2024 $140 · 2025 $315
Food & beverage: $315
| Company | Payments | Amount |
|---|---|---|
| Stemline Therapeutics Inc. | 2 | $60 |
| Novartis Pharmaceuticals Corporation | 2 | $50 |
| Boston Scientific Corporation | 1 | $31 |
| Genentech USA, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| Incyte Corporation | 1 | $22 |
| ABBVIE INC. | 1 | $21 |
| Merck Sharp & Dohme LLC | 1 | $18 |
| MILLICENT US INC | 1 | $18 |
Products named: Orserdu, KISQALI, Upsylon, Itovebi, Enhertu, Lynkuet, ZYNYZ, VENCLEXTA.
Industry payments across MD — which companies pay providers there.
